Menstrual Cycle-Aware Insulin Dosing for Glucose Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional medicament delivery devices do not account for variations in medicament dosage needs due to the menstrual cycle of the user, leading to increased risks of hyperglycemia or hypoglycemia.
Innovation Solution
A medicament delivery device that adjusts medicament dosages based on the user's menstrual cycle phase using sensors and a machine learning model to determine insulin sensitivity, allowing for real-time adjustments of basal and bolus dosages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional fixed dosages are delivered by the medicament delivery device, then the device operation is simple, but the risk of hyperglycemia or hypoglycemia increases due to not accounting for menstrual cycle variations
Solution Approach 1:
The medicament delivery device transitions from fixed dosages to dynamic dosages that automatically adjust based on detected menstrual cycle phase. The control system modifies basal and bolus dosages in real-time according to cycle phase, making the dosage regimen adaptive rather than static, thereby improving safety without requiring complex manual intervention
Solution Approach 2:
The device incorporates feedback loops where sensor data (temperature, heart rate, activity) is continuously monitored, processed to determine menstrual cycle phase, and used to adjust dosages accordingly. This closed-loop feedback system automatically responds to physiological changes, improving blood glucose control safety through real-time adaptation
2Measurement precision
If the device uses sensors and machine learning models to determine menstrual cycle phase, then dosage accuracy improves, but the device complexity increases
Solution Approach 1:
The device uses a multi-functional sensor system where the same sensors (temperature, heart rate, activity) serve multiple purposes: monitoring general health metrics and simultaneously detecting menstrual cycle phase. This universal approach improves measurement precision without proportionally increasing complexity, as the sensors already exist for other monitoring functions
Solution Approach 2:
The machine learning model automatically processes sensor data to determine menstrual cycle phase without requiring manual user input or intervention. The system self-calibrates and self-adjusts dosages based on detected phase, improving accuracy while minimizing the complexity of user interaction and manual configuration
3Manufacturing precision
If real-time dosage adjustments are made based on menstrual cycle phase, then blood glucose control improves, but the calculation complexity increases
Solution Approach 1:
The device pre-calculates and stores dosage adjustment factors for different menstrual cycle phases before real-time operation. When a phase is detected, the system retrieves pre-computed adjustment parameters rather than performing complex calculations from scratch, improving dosage precision while reducing real-time computational complexity
Solution Approach 2:
The control system adjusts dosages by modifying key parameters (basal rate, bolus factors, insulin-to-carb ratios) based on detected menstrual cycle phase. Rather than completely recalculating dosages, the system applies phase-specific parameter adjustments to baseline values, improving precision through targeted parameter modification while managing calculation complexity
Data Source
AI summary
Exemplary embodiments account for differing needs of a user over the menstrual cycle of the user to better control the blood glucose concentration of the user. The exemplary embodiments may be realized in control systems for medicament delivery devices that deliver medicaments, such as medicaments that regulate blood glucose concentration levels. Examples of such medicaments that regulate blood glucose concentration levels include insulin, glucagon, and glucagon peptide-1 (GLP-1) agonists. The exemplary embodiments are able to better tailor the dosages of the medicament delivered to the user with the medicament delivery device to reduce the risk of hyperglycemia and hypoglycemia and help reduce blood glucose concentration excursions.